Book chapter
Plasma-Induced Immunogenic Cancer-Cell Death
Redox Biology in Plasma Medicine, pp 145-155
2025
Abstract
Plasma technology is proposed as a local anticancer treatment modality. Currently used therapeutics for tumor mass debulking generally have limited direct effects on deeper layers of the tumor tissues. However, plasma-induced tumor cell death was shown to have pro-immunogenic properties. Tumor cells dying from immunogenic cell death (ICD) were demonstrated to provide improved immunostimulation. This enhanced the quality and quantity of adaptive antitumor immunity provided by T-cells. T-cells are significant effectors active against cancer cells, and several current clinical therapies aim at augmenting T-cell-tumor-cell interactions to mediate superior immune control of cancers. Plasma treatment was shown to set the stage for engaging such a cancer-immunity-cycle in different tumor types. Therefore, plasma technology may be helpful when combined with current oncology treatment modalities by providing increased tumor cell immunogenicity locally in the tumor. There is evidence that plasma-generated reactive species are one of the critical drivers of ICD induction in treated tumor cells, aligning with studies showing that this process is subject to redox control.
Metrics
15 Record Views
Details
- Title
- Plasma-Induced Immunogenic Cancer-Cell Death
- Creators
- Vandana MillerSander Bekeschus
- Contributors
- Sander Bekeschus (Editor)Thomas von Woedtke (Editor)
- Publication Details
- Redox Biology in Plasma Medicine, pp 145-155
- Publisher
- CRC Press
- Edition
- 1
- Resource Type
- Book chapter
- Language
- English
- Academic Unit
- Microbiology Department Internal Research
- Scopus ID
- 2-s2.0-85206051762
- Other Identifier
- 991021889789804721